Eloxx Pharmaceuticals, Inc. (ELOX)
13.34
+0.17
(+1.29%)
USD |
OTCM |
Oct 27, 16:00
Eloxx Pharmaceuticals Enterprise Value : -8.120M for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | -8.120M |
| October 26, 2026 | -8.807M |
| October 23, 2026 | -10.30M |
| October 22, 2026 | -9.008M |
| October 21, 2026 | -8.282M |
| October 20, 2026 | -8.605M |
| October 19, 2026 | -11.51M |
| October 16, 2026 | -9.372M |
| October 15, 2026 | -6.667M |
| October 14, 2026 | -12.68M |
| October 13, 2026 | -10.70M |
| October 12, 2026 | -5.900M |
| October 09, 2026 | -6.506M |
| October 08, 2026 | -0.6934M |
| October 07, 2026 | -1.904M |
| October 06, 2026 | -0.8953M |
| October 05, 2026 | 0.2349M |
| October 02, 2026 | 0.6386M |
| October 01, 2026 | 1.446M |
| September 30, 2026 | -0.1687M |
| September 29, 2026 | 0.2753M |
| September 28, 2026 | -1.42M |
| September 25, 2026 | -1.299M |
| September 24, 2026 | 2.616M |
| September 23, 2026 | 0.3358M |
| Date | Value |
|---|---|
| September 22, 2026 | 5.563M |
| September 21, 2026 | 7.420M |
| September 18, 2026 | 8.469M |
| September 17, 2026 | 8.873M |
| September 16, 2026 | 9.196M |
| September 15, 2026 | 11.70M |
| September 14, 2026 | 3.827M |
| September 11, 2026 | 1.607M |
| September 10, 2026 | 3.747M |
| September 09, 2026 | 4.917M |
| September 08, 2026 | 3.303M |
| September 04, 2026 | -1.42M |
| September 03, 2026 | -4.690M |
| September 02, 2026 | 1.971M |
| September 01, 2026 | -1.380M |
| August 31, 2026 | 5.724M |
| August 28, 2026 | -1.138M |
| August 27, 2026 | 2.616M |
| August 26, 2026 | 12.83M |
| August 25, 2026 | 15.90M |
| August 24, 2026 | 18.72M |
| August 21, 2026 | 22.70M |
| August 20, 2026 | 10.85M |
| August 19, 2026 | 11.31M |
| August 18, 2026 | 11.70M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Filana Therapeutics, Inc. | -51.36M |
| CorMedix, Inc. | 509.14M |
| Breakthrough Chemistry, Inc. | 0.241M |
| BioStem Technologies, Inc. | 20.64M |
| Cardiac Biotech Solutions, Inc. | 5.690M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.502M |
| Total Expenses (Quarterly) | 4.502M |
| EPS Diluted (Quarterly) | -0.6631 |
| Earnings Yield | -62.04% |
| Normalized Earnings Yield | -62.54 |